Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Tess A. O’Meara; Sara M. Tolaney

doi:10.18632/oncotarget.27877

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Tess A. O’Meara and Sara M. Tolaney _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:394-400. https://doi.org/10.18632/oncotarget.27877

Metrics: PDF 2408 views | Full Text 5231 views | ?

Abstract

Tess A. O’Meara1 and Sara M. Tolaney2

1 Department of Internal Medicine, Brigham and Women’s Hospital, Boston, MA, USA

2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Correspondence to:

Sara M. Tolaney,

email:

[email protected]

Keywords: breast cancer; immunotherapy; tumor mutational burden

Received: January 09, 2021 Accepted: January 19, 2021 Published: March 02, 2021

Copyright: © 2021 O’Meara and Tolaney. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Tumor mutational burden (TMB) is a promising tool to help define patients with triple-negative breast cancer (TNBC) most likely to benefit from immune checkpoint blockade (ICB) therapies. Roughly reflecting the degree of neo-antigens that tumors present to immune cells, TMB associates with multiple measures of tumoral immunogenicity and has proven clinically useful in cancers with relatively high mutation burden. TNBC carries higher TMB than other breast cancer subtypes, and recent data suggest that high-TMB TNBC cases may derive particular benefit from ICB in combination with chemotherapy (GeparNuevo, IMpassion130) or even ICB alone (KEYNOTE-119, TAPUR). Given the recent approval of pembrolizumab and atezolizumab in combination with chemotherapy for PD-L1-positive, metastatic TNBC, standardizing TMB calculation methods and cut-off values is of critical importance to deploy this clinical biomarker.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27877

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Abstract